Spruce Biosciences, Inc. Common Stock
SPRB
SPRB: Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
moreShow SPRB Financials
Recent trades of SPRB by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by SPRB's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Crystalline composition of tildacerfont and methods of use and preparation thereof Jul. 25, 2023
-
Patent Title: Corticotropin releasing factor receptor antagonists Jun. 07, 2022
-
Patent Title: Corticotropin releasing factor receptor antagonists May. 31, 2022
-
Patent Title: Corticotropin releasing factor receptor antagonists Apr. 26, 2022
-
Patent Title: Methods for treating testicular and ovarian adrenal rest tumors Apr. 19, 2022
-
Patent Title: Corticotropin releasing factor receptor antagonists May. 18, 2021
-
Patent Title: Corticotropin releasing factor receptor antagonists Dec. 01, 2020
Federal grants, loans, and purchases
Followers on SPRB's company Twitter account
Number of mentions of SPRB in WallStreetBets Daily Discussion
Recent insights relating to SPRB
Recent picks made for SPRB stock on CNBC
ETFs with the largest estimated holdings in SPRB
Flights by private jets registered to SPRB